Logo image of INO

INOVIO PHARMACEUTICALS INC (INO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INO - US45773H4092 - Common Stock

1.96 USD
+0.15 (+8.29%)
Last: 11/26/2025, 8:00:02 PM
1.9104 USD
-0.05 (-2.53%)
After Hours: 11/26/2025, 8:00:02 PM
Fundamental Rating

2

Overall INO gets a fundamental rating of 2 out of 10. We evaluated INO against 533 industry peers in the Biotechnology industry. The financial health of INO is average, but there are quite some concerns on its profitability. While showing a medium growth rate, INO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INO had negative earnings in the past year.
INO had a negative operating cash flow in the past year.
INO had negative earnings in each of the past 5 years.
INO had a negative operating cash flow in each of the past 5 years.
INO Yearly Net Income VS EBIT VS OCF VS FCFINO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -128.36%, INO is doing worse than 81.61% of the companies in the same industry.
With a Return On Equity value of -307.02%, INO is not doing good in the industry: 71.67% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -128.36%
ROE -307.02%
ROIC N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
INO Yearly ROA, ROE, ROICINO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INO Yearly Profit, Operating, Gross MarginsINO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

5

2. Health

2.1 Basic Checks

INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INO has more shares outstanding
Compared to 5 years ago, INO has more shares outstanding
There is no outstanding debt for INO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INO Yearly Shares OutstandingINO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
INO Yearly Total Debt VS Total AssetsINO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

INO has an Altman-Z score of -39.06. This is a bad value and indicates that INO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -39.06, INO is not doing good in the industry: 91.56% of the companies in the same industry are doing better.
INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -39.06
ROIC/WACCN/A
WACC8.48%
INO Yearly LT Debt VS Equity VS FCFINO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 1.66 indicates that INO should not have too much problems paying its short term obligations.
With a Current ratio value of 1.66, INO is not doing good in the industry: 80.49% of the companies in the same industry are doing better.
INO has a Quick Ratio of 1.66. This is a normal value and indicates that INO is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of INO (1.66) is worse than 79.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
INO Yearly Current Assets VS Current LiabilitesINO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.79% over the past year.
Looking at the last year, INO shows a very negative growth in Revenue. The Revenue has decreased by -73.82% in the last year.
Measured over the past years, INO shows a very negative growth in Revenue. The Revenue has been decreasing by -44.44% on average per year.
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.25%
Revenue 1Y (TTM)-73.82%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%N/A

3.2 Future

INO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.13% yearly.
Based on estimates for the next years, INO will show a very strong growth in Revenue. The Revenue will grow by 356.19% on average per year.
EPS Next Y52.28%
EPS Next 2Y27.09%
EPS Next 3Y22.34%
EPS Next 5Y17.13%
Revenue Next Year-25.9%
Revenue Next 2Y949.07%
Revenue Next 3Y735.89%
Revenue Next 5Y356.19%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INO Yearly Revenue VS EstimatesINO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
INO Yearly EPS VS EstimatesINO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INO. In the last year negative earnings were reported.
Also next year INO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INO Price Earnings VS Forward Price EarningsINO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INO Per share dataINO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

INO's earnings are expected to grow with 22.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.09%
EPS Next 3Y22.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (11/26/2025, 8:00:02 PM)

After market: 1.9104 -0.05 (-2.53%)

1.96

+0.15 (+8.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners19.03%
Inst Owner Change104.44%
Ins Owners0.52%
Ins Owner Change0.13%
Market Cap104.15M
Revenue(TTM)217.80K
Net Income(TTM)-87.60M
Analysts80
Price Target7.79 (297.45%)
Short Float %15.53%
Short Ratio6.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.92%
Min EPS beat(2)0.86%
Max EPS beat(2)44.99%
EPS beat(4)4
Avg EPS beat(4)24.57%
Min EPS beat(4)0.86%
Max EPS beat(4)44.99%
EPS beat(8)5
Avg EPS beat(8)9.12%
EPS beat(12)7
Avg EPS beat(12)8.41%
EPS beat(16)8
Avg EPS beat(16)0.48%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.23%
PT rev (3m)2.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 571.34
P/FCF N/A
P/OCF N/A
P/B 3.65
P/tB 3.65
EV/EBITDA N/A
EPS(TTM)-2.49
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-1.78
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0
BVpS0.54
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -128.36%
ROE -307.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.65%
Cap/Sales 48.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -39.06
F-Score1
WACC8.48%
ROIC/WACCN/A
Cap/Depr(3y)20.92%
Cap/Depr(5y)27.95%
Cap/Sales(3y)90.66%
Cap/Sales(5y)72.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.25%
EPS Next Y52.28%
EPS Next 2Y27.09%
EPS Next 3Y22.34%
EPS Next 5Y17.13%
Revenue 1Y (TTM)-73.82%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%N/A
Revenue Next Year-25.9%
Revenue Next 2Y949.07%
Revenue Next 3Y735.89%
Revenue Next 5Y356.19%
EBIT growth 1Y18.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.16%
OCF growth 3YN/A
OCF growth 5YN/A

INOVIO PHARMACEUTICALS INC / INO FAQ

Can you provide the ChartMill fundamental rating for INOVIO PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 2 / 10 to INO.


Can you provide the valuation status for INOVIO PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to INOVIO PHARMACEUTICALS INC (INO). This can be considered as Overvalued.


Can you provide the profitability details for INOVIO PHARMACEUTICALS INC?

INOVIO PHARMACEUTICALS INC (INO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for INO stock?

The Earnings per Share (EPS) of INOVIO PHARMACEUTICALS INC (INO) is expected to grow by 52.28% in the next year.